Human Microbiome Market is Estimated to Witness High Growth Owing to Rising R&D Investments
Author : naufan cmi | Published On : 23 Jan 2024
The human microbiome refers to the genetic material of microorganisms such as bacteria, viruses, and fungi that reside on and inside the human body. The human microbiome plays a crucial role in regulating various bodily functions including immunity, metabolism, and gastrointestinal health. Advancements in next-generation sequencing technologies and microbiology techniques have enabled extensive research on the human microbiome. Key players are developing microbiome-based therapies and diagnostics targeting various diseases such as cancer, diabetes, and neurological disorders.
The global human microbiome market is estimated to be valued at US$ 329 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2027, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Rising R&D investments by key players in human microbiome-focused drug development initiatives is estimated to propel the growth of the human microbiome market over the forecast period. For instance, in November 2021, Vedanta Biosciences, a human microbiome company, raised $275 million in a Series E financing round led by BlackRock to advance its clinical-stage pipeline investigating the human microbiome's potential to treat immune-mediated and metabolic diseases.
Additionally, growing awareness regarding the relationship between gut health and various disease conditions is anticipated to boost the adoption of microbiome-based therapies. Companies are developing microbiome profiling diagnostic kits to determine microbiome composition and identify disease biomarkers. Such advancements are expected to accelerate the adoption of targeted microbiome therapies.
SWOT Analysis
Strength: The human microbiome market offers new opportunities for developing microbiome-based therapeutics. Several clinical trials are being conducted to evaluate microbiome-based therapies. Growing awareness regarding gut health and its link to various chronic diseases is driving research interest in this field.
Weakness: Extensive research is still required to fully understand the complex relationship between the human microbiome and disease states. The human microbiome is a complex ecosystem and the effects of probiotics and microbiome-based therapies can vary significantly between individuals. Safety and efficacy validation of microbiome-based drugs also poses a challenge.
Opportunity: The development of next-generation sequencing technologies has enabled comprehensive characterization of the human microbiome. This is spurring new discoveries about microbiome dysbiosis associated with various diseases. Identifying disease-specific microbiome signatures offers opportunities for developing microbiome-guided precision therapies. The increasing popularity of nutraceuticals and functional foods also presents commercial opportunities.
Threats: Stringent regulatory approvals and long development timelines add to the costs and risk of commercializing microbiome-based therapies. Intellectual property protection for microbiome-based innovations also remains a challenge. Low consumer awareness regarding the human microbiome and probiotics limits the market potential for some products.
Key Takeaways
The Global Human Microbiome Market Size is expected to witness high growth in the coming years. According to estimates, the market size was valued at USD326 million in 2019 and is projected to reach USD876 million by 2028, registering a CAGR of around 13% over the forecast period.
North America currently dominates the global market owing to large public and private sector investments in microbiome R&D. The US has emerged as a major hub for microbiome-based drug development. For instance, Seres Therapeutics is conducting phase 3 clinical trials of SER-109, an oral microbiome therapeutic for recurrent C. difficile infection. However, Asia Pacific is anticipated to be the fastest growing regional market in the upcoming years. Countries like India, China and Japan are investing aggressively in gut microbiome research and fecal microbiota transplantation.
Key players operating in the human microbiome market are Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Vedanta Biosciences, 4D Pharma, Evelo Biosciences, and Enterome Bioscience. These companies are focusing on developing promising pipelines of microbiome-based therapies targeting multifarious disease applications like immune-oncology, metabolic disorders, infectious diseases and more.
Get more insights on this topic:
https://www.rapidwebwire.com/human-microbiome-market-demand/
Check below trending articles on this topic:
https://www.dailyprbulletin.com/telecom-towers-market-demand-size-and-share/
